Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
Regeneron Pharmaceuticals (REGN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Regeneron Pharmaceuticals's actual EPS was $12.89, beating the estimate of $8.61 per share, resulting in a 49.77% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
